Paloma Partners’s Moleculin Biotech MBRX Stock Holding History

Paloma Partners’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-16	Closed	-$34K	–	2301
2020 Q2	$34K	Buy	+16	New	+$37.9K	﹤0.01%	2015

Other funds holding MBRX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

WIC

Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ECM

ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return

Paloma Partners's MBRX Position: Q3 2020 in Review

Paloma Partners sold out of Moleculin Biotech (MBRX) in Q3 2020, closing a stake of 16 shares — an estimated $34K sold.

Paloma Partners first reported a position in MBRX in Q2 2020 and held it in 1 quarter. The position peaked at $34K in Q2 2020. 18 funds tracked by Wall St. Rank hold MBRX as of Q3 2020.

Paloma Partners reported no remaining Moleculin Biotech position as of Q3 2020 after selling out during the quarter.
Paloma Partners sold 16 Moleculin Biotech shares in Q3 2020, an estimated $34K.
Paloma Partners first reported a position in Moleculin Biotech in Q2 2020 and held it in 1 quarter.
Paloma Partners's Moleculin Biotech position peaked at $34K in Q2 2020.
18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.